GT BIOPHARMA, INC. Other Nonoperating Income (Expense)
GT BIOPHARMA, INC. (GTBP) reported Other Nonoperating Income (Expense) of $156.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Income Statement › Other Income
us-gaap:OtherNonoperatingIncomeExpense · last filed 2026-08-14
- GT BIOPHARMA, INC. other nonoperating income (expense) for the quarter ending 2025-12-31 was $0.00.
- GT BIOPHARMA, INC. other nonoperating income (expense) for the quarter ending 2025-09-30 was $0.00.
- GT BIOPHARMA, INC. other nonoperating income (expense) for the quarter ending 2025-06-30 was $156.00K.
- GT BIOPHARMA, INC. other nonoperating income (expense) for the quarter ending 2024-06-30 was -$27.00K, a 112.27% decline year-over-year.
- GT BIOPHARMA, INC. other nonoperating income (expense) for fiscal 2025 was $156.00K.
- GT BIOPHARMA, INC. other nonoperating income (expense) for fiscal 2023 was $20.00K.
- GT BIOPHARMA, INC. other nonoperating income (expense) for fiscal 2021 was $38.00K.
| Period end | Other Nonoperating Income (Expense) 3 month | Other Nonoperating Income (Expense) 3 month as first filed | Other Nonoperating Income (Expense) 6 month | Other Nonoperating Income (Expense) 9 month | Other Nonoperating Income (Expense) 9 month as first filed | Other Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-06 | $156.00K derived: sum of 3 quarters · filed 2026-08-14 | $156.00K 10-K · filed 2026-03-02 | ||
| 2025-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q 6 month · filed 2026-03-06 | $156.00K derived: sum of 2 quarters · filed 2026-08-14 | $156.00K 10-Q/A · filed 2026-03-06 | |||
| 2025-06-30 | $156.00K 10-Q · filed 2026-08-14 | $156.00K 10-Q · filed 2026-08-14 | ||||
| 2024-06-30 | -$27.00K 10-Q/A · filed 2026-03-06 | $0.00 derived: sum of 2 quarters · filed 2026-03-06 | -$580.00K derived: sum of 3 quarters · filed 2026-03-06 | -$364.00K derived: sum of 4 quarters · filed 2026-03-06 | ||
| 2024-03-31 | $27.00K 10-Q · filed 2025-05-15 | -$553.00K derived: sum of 2 quarters · filed 2025-05-15 | -$337.00K derived: sum of 3 quarters · filed 2025-05-15 | -$117.00K derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2023-12-31 | -$580.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | -$364.00K derived: sum of 2 quarters · filed 2025-02-21 | -$144.00K derived: sum of 3 quarters · filed 2025-02-21 | $20.00K 10-K · filed 2025-02-21 | ||
| 2023-09-30 | $216.00K 10-Q · filed 2023-11-01 | $436.00K derived: sum of 2 quarters · filed 2023-11-01 | $600.00K 10-Q · filed 2023-11-01 | |||
| 2023-06-30 | $220.00K 10-Q · filed 2023-08-07 | $384.00K 10-Q · filed 2023-08-07 | ||||
| 2023-03-31 | $164.00K 10-Q · filed 2023-05-15 | |||||
| 2022-09-30 | $107.00K 10-Q · filed 2023-11-01 | $143.00K derived: sum of 2 quarters · filed 2023-11-01 | $151.00K 10-Q · filed 2023-11-01 | $157.00K derived: sum of 4 quarters · filed 2023-11-01 | ||
| 2022-06-30 | $36.00K 10-Q · filed 2023-08-07 | $44.00K 10-Q · filed 2023-08-07 | $50.00K derived: sum of 3 quarters · filed 2023-08-07 | $82.00K derived: sum of 4 quarters · filed 2023-08-07 | ||
| 2022-03-31 | $8.00K 10-Q · filed 2023-05-15 | $14.00K derived: sum of 2 quarters · filed 2023-05-15 | $46.00K derived: sum of 3 quarters · filed 2023-05-15 | |||
| 2021-12-31 | $6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $38.00K derived: sum of 2 quarters · filed 2022-10-31 | $38.00K 10-K · filed 2022-03-28 | |||
| 2021-09-30 | $32.00K 10-Q · filed 2022-10-31 | -$501.00K 10-Q · filed 2021-11-10 | $32.00K 10-Q · filed 2022-10-31 | $654.00K 10-Q · filed 2021-11-10 | ||
| 2020-09-30 | $931.00K 10-Q · filed 2021-11-10 | $17.43M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |